Article and Video CATEGORIES

Cancer Journey

Search By

Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Author
GRACE Videos and Articles
Image

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Get more information about the FLAURA Trial and TIGER-1 Trial.

 

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:

Forum Discussions

Hi ramosking,  Welcome to Grace.  I'm sorry you're suffering.  It doesn't sound like you have a pancoast tumor. It does seem like you should see your PCP or a pulmonologist for...

Hey, So I went to the Doctor and explained all my symptoms I was having, They did some examining by listening to my lungs with a stethoscope, They said my lungs...

I hope you find some help through your doc or PT. 

Take care,

Janine

Hi Revtoby, Welcome to Grace.  I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Recent Comments

JOIN THE CONVERSATION
Xalkori (crizotinib) is a…
By philipphilip on
I hope you find some help…
By JanineT GRACE … on
Went to doctor
By ramosking on
Hi ramosking,  Welcome to…
By JanineT GRACE … on